Search results
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
Zacks via Yahoo Finance· 2 years agoIpsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in...
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
Benzinga via Yahoo Finance· 11 months agoIpsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE...
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
Zacks via Yahoo Finance· 2 years agoThe biotech sector has been in the spotlight in the past week with important pipeline and regulatory...
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
Benzinga via Yahoo Finance· 1 year agoIpsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in...
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Benzinga via Yahoo Finance· 2 years agoIpsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for...
Why These Two Biotech Stocks Blasted Higher This Week
Motley Fool· 1 year agoTwo somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing...
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Benzinga via Yahoo Finance· 2 years agoMerrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported...
AbbVie, Ipsen Terminate Partnerships With Exicure As Bankruptcy Concern Looms
Benzinga via Yahoo Finance· 1 year agoExicure Inc (NASDAQ: XCUR) announced the termination of its collaboration agreements with AbbVie Inc...
Stock Market Gains Led By Tech Stocks As Earnings Season Begins; Retail Stocks Sag
Investor's Business Daily· 1 year agoThe stock market on Monday added to last week's rally as earnings season began. But some retail...
Why Merrimack Shares Are Surging Over 200% Today?
Benzinga via Yahoo Finance· 2 years agoIpsen SA (OTC: IPSEY) announced that the Phase 3 NAPOLI 3 trial of Onivyde plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its...